Osimertinib + ramucirumab

2 trials

Sponsors

Wakayama Medical University

Conditions

Lung CancerTo assess the efficacy and toxicity of Osimertinib plus ramucirumab

Unknown Phase

A Phase Ib study of osimertinib with ramucirumab in EGFR mutated lung adenocarcinoma patients. (LY3009806-IIT-01)

Active, not recruitingJPRN-UMIN000030142

Wakayama Medical UniversityTo assess the efficacy and toxicity of Osimertinib plus ramucirumab

Start: 2017-11-28Target: 6Updated: 2026-06-29

Monitoring EGFR mutation status with cell-free DNA: a prospective exploratory analyses of phase Ib study of osimertinib plus ramucirumab in lung adenocarcinoma patients with EGFR T790M mutation

Active, not recruitingJPRN-UMIN000030164

Wakayama Medical UniversityLung Cancer

Start: 2017-11-29Target: 6Updated: 2026-06-29